I am not usually endeared to extreme points of view, but I am going to argue that it is extremely unwise to use aminoglycoside-containing otic drops to treat middle ear disease, especially considering what we know about inner ear toxicity -not to mentio n what lawyers know about it.
There is no question that topieal aminoglycosides have historically had a role to play in the treatment of external otitis, post-tympanostomy tube otorr hea seco ndary to an infectio n or tubal gran ulorna, and so-called safe chronic suppurat ive otitis media, with or without cholesteato ma. And topieal aminoglycosides are certainly effective against the usual pathogens: Pseudomo nas aeruginosa , Stap hyloeoeeus aureus, Escherichia coli, Proteus species, and anaerobes.
Nevertheless, all aminoglycosides have a dark side: They can cause ototoxici ty. In the case of systemic gentamicin, ototoxici ty appears to be primarily related to the dura tion of treatrnent, especially when the treatment course exceeds lOto 14 days . It is also impor tant to realize that gentamici n-ind uced ototoxicity tends to be primari ly vestibular (figures I and 2), although cochleotoxicity is seen as weil.
Mechanism of aminoglycoside transport
Not all aminoglycosides are vestibulotoxic. Streptomycin and gentamicin, for example, are primarily vestibulotoxic, while neomycin appears to be primarily cochleotoxic. The differe nce in the types of toxicity is related to the particular aminoglycos ide molecule's end attac hment.
We have good scientific ev idence that when a topieal aminoglycosi de reaches the middle ear, it can pass into the inner ear, primaril y through the round window mem-brane. Th is is not merely a passive process of diffusion; there is an active transport mecha nism that delivers the aminog lycosi de across the membrane itself. The existence of active transport has been confi rmed in numero us animal studies, as observe d in the passage of tagged substances, including horseradish peroxidase, 1311-labeled ions, albumin, and neornycin . The existence of this mechanism has also been confirmed by doc umente d observations of histopathologic changes in the inner ear (e.g., loss of hair cells and degeneration of the erista ampullaris of the semicircular canals) and by the observation of in vivo electrophysio logic changes during auditory brainstem-· evoked response testing, electrocochleograp hy, and otoacoustic reflex testingo Aminoglycoside ototoxicity in humans Despite our knowledge that aminog lycos ides are toxic to the inner ears of animals, evidence of topieal ototoxic ity in humans has been more difficult to discern. Nevertheless, this does not mean that aminoglycoside-induced ototoxicity in humans does not occur. In fact, I suspec t that it is probabl y more common than most physicians believe. For vario us reaso ns, topieal ototoxicity is probably under-reported by both patie nts and physic ians.
In order to apprecia te why topieal aminoglycosi deinduced oto toxicity seems to be so uncommon, it is useful to look at certain middle ear anatomic factors, as weil as individual patien t and physician factors.
A natomicfa ctors. Aminoglycosideentry into the middle ear is influenced by the size of the tympanic membrane perforation and the viscosity of the preparation itself. Drops cannot easily pass through perforations that are very small. Likewise, drops that are very viscous cannot pass through most perforations, regardless of their size .
The status of the eustachian tube also has an effec t on inner ear absorption. In a patient whose eustachian tube is open, dro ps that reach the middle ear space will not reside there long enough to be transported to the inner ear; instead, they will migrate down the eustachian tube. 
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Other deterr ent s to absorpti on into the inner ear are phy sical barriers, such as pus and mucu s, which can proteet the round window membrane. A significant number of patient s ha ve muc osal webs in the round window niche that proteet the round window membrane and prevent drop s from bein g absorbed by the inner eal'. Finally , variability in the permeability of an individual's round window memb rane has an effect on which patient s might abso rb drops into the inner eal'.
Patientfactors. One reason topie al ototoxicity is probabl y under-reported is that patient s appear to be resigned to the fact that any hearin g or vestibul ar loss they might experience is the result of thei r underlying pathology rather than its treatment. Second , in a somew hat analogous fashion , reco very of vestibular function oCCUl'Sin up to 50 % of patient s who discontinue sys temic ge ntamicin therapy as soo n as symptoms of ototoxicity occur; with their pathology resolved, these patient s often pay little attenti on to the ototoxicity . Third, patient s who experience a vestibular loss on only one side are usually able to comp ensate for it if their contralatera l side is functioning weil ; aga in, ifthe problem is manageable , the ototoxicity is not as noticeable. Finally, some patient s are simply more susceptible to ototoxicit y than are others.
Physicianfactors. We physicians have not done a good job of recog nizing topi eal ototoxicity, primarily because we fail to entertain the po ssibility. Also, we do not take a thorough enough history, and we do not conduct the bedside tests of c1inical vestibular funct ion that would allow us to draw a co nclusion as to whether a vestibular loss is present. The se tests-specifi cally, the high-frequ ency head-thrust (Halma gyi ) man eu ver, the head-shake test for nystagmu s, and the oscillopsia test-can be easi ly performed in the c1inical setting oFinall y, we rarely have a pre-event audiogra m or electron ystagmogram that serves as a baselin e, and most of our offi ees are not equipped for aircaloric, closed-loop cal oric , or rotational-chair testingo
Investigational gentarniein ototoxicity
We at the University of Toronto became aware that topie al gentamicin was primarily toxic to the vestibular portion of the inner ear in the late 1980s, when we began using it to treat patient s who had incapacitating unilateral Meni eres disease. Since then, our method for chemical J81":õ f ge ntamiein and I mg/ml of betam eth asone. All three patient s had used these drap s for a prol an ged period , even after their ears had stopped dise harging . Fortunately, preeve nt audiomet ry results were ava ilable on all three patient s. Follow -up audio metry revealed that there was no signifieant eha nge in sensorineura l reserve.
It is difficult to think of many faetors other than ge ntam iein toxieit y that eould have ea use d these patient s' bilateral peripheral vestibular loss, but we never theless earefully ruled out other eauses by performing extensive immunologic and sero log ic testing, intrae ranial imagi ng, adva nced brain stem -evoked response audiometry, and vestibular testin go The only conelu sian we eould reae h was that the topieal ge ntamicin had eau sed the ototoxicity. At that point , everything we thought we knew about topie al gent amiein and its effeets on the inner ear seemed to fall into place .
Sinee then, we have now identi fied 30 patient s whom we believe have been affeeted by inad vertent ototoxieity ea use d by eommerei all y availab le ge nta miein/be tameth asone drops. Most of these patient s had used these drap s for approx imately 14 days on ave rage. Forthe most part, their toxicity appea red to be ves tibular rather than eoe hlear, and I suspeet that this is the main reason we faile d to reeognize it c1iniea lly. Whe n se nsor ineuraI hearing loss was present , it usually was ide ntified in the higher frequeneies.
When we first publ ished our findings, they were quite controversial.' We heard er itieisms that perhaps the vestibular loss was the result of the endotoxi ns or exo toxins fra m the infee tion itself or the res ult of a eoineident al vestibular neur oniti s. Oth ers spee ulated that the vesti bular loss had been present prior to ge ntamiein therapy but had go ne unrecogni zed. All of these eo neerns were valid.
We faeed a dilemma as to how we eould pra ve our theory that eommereially available ge ntamiein prepara- 
Inadvertent gentarniein ototoxieity
Wh at drew our attention to the fae t that ge ntamiein dro ps ean be toxic if they are used long enough is the faet that three eo nsee utive patients ea me to our instituti on eo mplainin g of atax ia, imb alanee, and oseillopsia as aresult of a bilateral periph eral vestibular dysfunetion follo wing topieal ge ntamiein therap y. All three patient s had had defeets in their tymp anie membranes, and all had used a eo mbination gentamie in/betame thaso ne produ et that is available in Canada and is the most commonly preserib ed a ta topiea l agent in Eur ope. Thi s praduet eontains 3 mg/ml ablation of vestibular funetion with intra tympanie gentamiein has beeome reeognized as an accepted for m of treatm ent for Me niere' s disease.' Re views by Blakley-and Gustafsa n and Pensak' reee ntly doeum en ted that intraty mpanie gen tamie in eontrolled ver tigo in 80 to 100% of pat ients with Meniere's disease. Th ey found that some degree of eoe hleotox ieity did oeeur, but for the most part it did not appear to be related to the frequeney or length of treatm ent or to the amo unt of the overall dosage. Some patient s also ex perieneed a redu etion in tinnitus and aural pressure. Of interest, we now see m to have some evidenee that the incidenee of failed vertigo eontrol is hig her in Menieres disease patient s whose vestibul ar suppress ia n is ineompl ete.
Durin g our initial ge ntamiein ablations in the late 1980s, we deli vered approx imately 1.5 mi of a buffered ge ntamiein solution that eontained apprax imately 27 mg/ml of gentamie in. (This eo neentration is appraximately 10 times stra nger than the gentamiein in eomm ercia lly avai lable drop s in the Uni ted States.) We passed the solution through a simple butterfly eatheter that had the needIe end eut off and then thrau gh polyethylene tubin g that had been plaeed thraugh a myringotomy ineision. We administered three instillations per day for 3 days, and then we removed the eatheter. The gentamiein wo uld pool in the ra und window niehe and wo uld then be absorb ed in the inner ear. An imp ortant point to keep in mind is that although our patient s rarely became dizzy while these ablations were being perform ed, many beeame severely dizzy I to 3 day s later in a delayed fashion.
We were abIe to objeeti vely det ermin e that the gentamiein was effeetive in relieving the symptoms of Men iere' s disease. Alth ough Men iere' s disease is a fairly caprieious eondition that is mark ed by periods of remi ssion and exaeerbation, we were able to doeum ent that most of the 24 patient s we tested ex perieneed statistiea lly significa nt deafferent ation of vestibular funetion, as measured by ehanges in ea lorie exe itability differenees (figure 3) . Weil over half of these patient s exhibited no response to iee-water ca lories. eomm ereially available gentamiein/betamethasone four times a day, a regi men that is similar to the one used for the treatment of a diseh arging ear. They were asked to eontinue taking the drops until they beeame dizzy for 2 eo nsee utive days, and then to stop.
One to 6 month s followin g ablation, we performed repeat audiograph y and eleetron ystagmo graphy. Wh at we found faseinated us ( figure 4 ). Most patient s who beeame dizzy did so approx imately 12 days after they had begun therapy; the earlies t episode of dizziness occurred on day 7. Of the 20 patient s, 15 experieneed a signifiea nt ehan ge in ealorie aetivity, 10 did not respond to iee-w ater calories, 10 experieneed a signifieant worsening of their hearing, and eight eontinued to have a small perforation ; onlyone patient showed any improvement in hearin g.
Th is study proved to us that topieal antib ioties eould pass throu gh a ventil ation tube , into the mid dle ear, then into the inner ear. The faet that toxieity oeeurred in a delayed fashion suggested that the gentamiein in the inner ear had eoneentrated gradually. Of eour se, we were disappointed that half our patient s experien eed a deteri oration of their hearing. We suspeet the explanati on for this is that ears in patient s with Men iere' s disease are probabl y more sensitive to the effee ts of gent amiein than are norm al ears.
